Contract revenues - Morphomer Tau small molecule - 2018 license agreement with Eli Lilly and Company (Details) - CHF (SFr) SFr in Thousands |
6 Months Ended | |
|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Contract revenues | ||
| Revenue from contracts with customers | SFr 16,232 | SFr 2,296 |
| 2018 License Agreement with Eli Lilly and Company | ||
| Contract revenues | ||
| Collaborative agreement, upfront payments received | 10,000 | |
| Milestone payment received | 1,000 | |
| Revenue from contracts with customers | 11,000 | |
| 2018 License Agreement with Eli Lilly and Company | Maximum | ||
| Contract revenues | ||
| Collaborative agreement, potential amount receivable if certain conditions are fulfilled | SFr 1,700,000 | |